Development of a patient decision aid for superficial basal cell carcinoma.
Lieke C J van DelftBrigitte A B EssersP J NelemansK MosterdN W J Kelleners-SmeetsPublished in: The British journal of dermatology (2020)
Patients with superficial basal-cell carcinomas (sBCC) may be offered several treatment options including surgery, imiquimod, 5-fluorouracil (5FU), or photodynamic therapy (PDT). (1, 2) Patient decision aids (PDA) are tools to assist patients and physicians in shared decision making; a recent study showed that patients with BCC would like to participate in decision making. (3) Stacey et al. provided evidence showing that PDAs helped patients improve knowledge of their disease, possible treatments and risk-assessment. (4) Junn et al. recently described the development of a paper-based PDA for patients with sBCC with limited life expectancy that weighs benefits and risks of treatments versus watchful waiting. (5) We describe the development of a digital PDA for all patients with sBCC. The PDA was developed in line with the International Patient Decision Aid Standards (IPDAS). (6).
Keyphrases
- photodynamic therapy
- decision making
- end stage renal disease
- risk assessment
- ejection fraction
- newly diagnosed
- healthcare
- chronic kidney disease
- case report
- primary care
- prognostic factors
- peritoneal dialysis
- minimally invasive
- basal cell carcinoma
- human health
- acute coronary syndrome
- mesenchymal stem cells
- atrial fibrillation
- coronary artery disease
- single cell
- climate change
- cell therapy
- heavy metals
- percutaneous coronary intervention